Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801060 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00801060 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 40 participants.
The verdict
NCT00801060, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, open-label, multicenter study in subjects with previously untreated CLL. It is designed to evaluate safety and efficacy of fludarabine, cyclophosphamide, rituximab (FCR) and lumiliximab versus FCR alone.
Interventions
- DRUG FCR
- DRUG Lumiliximab + FCR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00801060
The ClinicalTrials.gov registry entry for NCT00801060 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FCR is the first listed.
NCT00801060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00801060 about?
NCT00801060 is a clinical study titled "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)". This is a Phase 2, randomized, open-label, multicenter study in subjects with previously untreated CLL. It is designed to evaluate safety and efficacy of fludarabine, cyclophosphamide, rituximab (FCR) and lumiliximab versus FCR alone.
What is the current status of trial NCT00801060?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-02. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00801060?
The interventions under investigation include: FCR (DRUG), Lumiliximab + FCR (DRUG).
Who is sponsoring clinical trial NCT00801060?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.